Table 24 Characteristics of patients with atrial fibrillation using VKAs or OAC medications compared to [4]
| Â | Â | VKA | Dabigatran | Rivaroxaban | Apixaban |
|---|---|---|---|---|---|
N (%) | Paper | 42% | 29% | 13% | 16% |
| Â | UKW_11 | 66% | 8% | 22% | 6% |
| Â | UKW_16 | 48% | 9% | 26% | 19% |
Males (%) | Paper | 57% | 55% | 50% | 50% |
| Â | UKW_11 | 59% | 62% | 61% | 63% |
| Â | UKW_16 | 61% | 66% | 62% | 58% |
Age <65 | Paper | 22% | 24% | 17% | 15% |
| Â | UKW_11 | 12% | 21% | 25% | 17% |
| Â | UKW_16 | 10% | 9% | 21% | 15% |
Age 65 to 74 | Paper | 33% | 35% | 33% | 31% |
| Â | UKW_11 | 28% | 29% | 28% | 22% |
| Â | UKW_16 | 25% | 25% | 29% | 25% |
Age 75 to 84 | Paper | 31% | 28% | 29% | 31% |
| Â | UKW_11 | 45% | 35% | 34% | 40% |
| Â | UKW_16 | 46% | 49% | 36% | 42% |
Age ≥85 | Paper | 13% | 13% | 21% | 22% |
| Â | UKW_11 | 15% | 15% | 13% | 21% |
| Â | UKW_16 | 19% | 17% | 14% | 18% |